Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug
18 November, 2019, 3:08 am
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
WASHINGTON (Reuters) – Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said the decision meant it had all the needed regulatory approvals and would close the acquisition on […]
